Product Description: Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.
Applications: COVID-19-immunoregulation
Formula: C10H6NNaO3
References: [1]Wang J, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006 Aug 4;281(31):22021-8./[2]Albuquerque EX, et al. Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol. 2013 Apr 15;85(8):1027-32./[3]Małaczewska J, et al. Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice. Cent Eur J Immunol. 2014;39(1):6-13.
CAS Number: 2439-02-3
Molecular Weight: 211.15
Compound Purity: 99.79
Research Area: Inflammation/Immunology; Neurological Disease; Endocrinology
Solubility: DMSO : 50 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL
Target: Apoptosis;CXCR;Endogenous Metabolite;GPR35 ;iGluR
English
Deutsch
